Stock PKTX PROTOKINETIX, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:17:55 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.017 USD +13.33% Intraday chart for ProtoKinetix, Incorporated -8.11% -10.53%
Mar. 29 ProtoKinetix, Incorporated announced a financing transaction CI
Mar. 20 ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 18.31 25.03 28.15 29.74 8.444 6.578
Enterprise Value (EV) 1 18.18 24.65 27.95 29.68 8.418 6.558
P/E ratio -15 x -5.83 x -3.61 x -12.5 x -4.29 x -1.9 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -15 x -5.88 x -3.66 x -12.8 x -4.55 x -17.9 x
EV / FCF -589 x 35.4 x 14.6 x -276 x -38 x -24.5 x
FCF Yield -0.17% 2.82% 6.85% -0.36% -2.63% -4.08%
Price to Book 75.1 x 44.7 x 66.8 x 84.3 x 20.4 x 15.1 x
Nbr of stocks (in thousands) 257,952 275,017 284,310 297,393 317,430 346,213
Reference price 2 0.0710 0.0910 0.0990 0.1000 0.0266 0.0190
Announcement Date 3/12/19 2/19/20 3/5/21 3/10/22 3/17/23 3/20/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -1.213 -4.195 -7.641 -2.326 -1.849 -0.3672
EBIT 1 -1.216 -4.198 -7.644 -2.329 -1.907 -0.4155
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.216 -4.198 -7.644 -2.329 -1.907 -0.4155
Net income 1 -1.216 -4.198 -7.644 -2.329 -1.907 -0.4155
Net margin - - - - - -
EPS 2 -0.004747 -0.0156 -0.0274 -0.007980 -0.006204 -0.0100
Free Cash Flow 1 -0.0308 0.6962 1.915 -0.1074 -0.2215 -0.2674
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/12/19 2/19/20 3/5/21 3/10/22 3/17/23 3/20/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 0.14 0.38 0.19 0.06 0.03 0.02
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.03 0.7 1.92 -0.11 -0.22 -0.27
ROE (net income / shareholders' equity) -393% -1,041% -1,553% -599% -493% -96.9%
ROA (Net income/ Total Assets) -180% -576% -906% -318% -262% -55%
Assets 1 0.6745 0.7286 0.8441 0.7323 0.7273 0.7547
Book Value Per Share 2 0 0 0 0 0 0
Cash Flow per Share 2 0 0 0 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/12/19 2/19/20 3/5/21 3/10/22 3/17/23 3/20/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PROTOKINETIX, INCORPORATED Stock ProtoKinetix, Incorporated
-10.53% 6M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.86B
LONZA GROUP AG Stock Lonza Group AG
+45.09% 41.36B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 42.74B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PKTX Stock
  4. Financials ProtoKinetix, Incorporated